All posts by: Michael Zand

About Michael Zand

​Orchard Therapeutics Closes $110 Million Series B for Gene Therapy – Equities.com

Continue reading

2017-12-21 NEWS

Equities.com

​Orchard Therapeutics Closes $110 Million Series B for Gene Therapy
Equities.com
Orchard’s lead product, OTL-101, is an autologous ex-vivo lentiviral gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare and life-threatening inherited disorder of the immune system

Continue reading

2017-12-21 NEWS

Science Daily

Seasonal images reveal the science behind stem cells
Science Daily
“I’m working with Professor Richard Oreffo and Dr Rahul Tare from the University’s Centre for Human Development, Stem Cells and Regeneration who are trying to create and grow cartilage in the lab using a patients’ own (autologous) stem cells to then be

and more »

Continue reading

2017-12-21 NEWS

Phys.Org

Seasonal images reveal the science behind stem cells
Phys.Org
“I’m working with Professor Richard Oreffo and Dr Rahul Tare from the University’s Centre for Human Development, Stem Cells and Regeneration who are trying to create and grow cartilage in the lab using a patients’ own (autologous) stem cells to then be

and more »